Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding the impact of Takeda’s late-stage oncology pipeline or tracing how plasma-derived therapy margins shift after a manufacturing upgrade can take hours when you rely on raw SEC documents alone. Each Takeda annual report 10-K simplified (filed as Form 20-F) exceeds 200 pages, and every 6-K update is packed with clinical-trial data and global revenue details. If you have ever searched for “Takeda SEC filings explained simply” or wondered where to find Takeda insider trading Form 4 transactions, you know the challenge of stitching these disclosures together.
Stock Titan solves that problem with AI-powered summaries that translate technical language into clear insights. Need the latest Takeda quarterly earnings report 10-Q filing? Our platform highlights pipeline milestones, segment sales, and R&D tax credits in seconds. Real-time alerts flag Takeda Form 4 insider transactions in real-time so you can monitor executive stock movements before markets react. You can also dive into Takeda proxy statement executive compensation, follow Takeda 8-K material events explained, and compare historical numbers with one click—no manual cross-referencing required.
Whether you’re assessing valuation sensitivity to rare-disease approvals or tracking cash-flow effects from neuroscience partnerships, Stock Titan provides comprehensive coverage of all forms—including 20-F, 6-K, 8-K, and of course Takeda executive stock transactions Form 4. Use our AI to perform Takeda earnings report filing analysis, spot trends across geographies, and understand Takeda SEC documents with AI before making your next move. Complex science becomes actionable data—updated the moment EDGAR releases.
Takeda Pharmaceutical (NYSE:TAK) has filed its annual Form 20-F report for foreign issuers. The filing appears to be a standard annual report containing detailed financial information, segment performance data, and regulatory disclosures across their pharmaceutical product portfolio including key drugs like Entyvio, Takhzyro, and Vyvanse. The report includes comprehensive breakdowns of revenue by therapeutic areas including Gastroenterology, Rare Diseases, PDT (Plasma-Derived Therapies), Oncology, Vaccines, and Neuroscience segments.
Takeda Pharmaceutical held its 149th Annual General Meeting of Shareholders on June 25, 2025, where several key resolutions were passed. The meeting addressed the company's performance for FY2024 (April 1, 2024 to March 31, 2025).
Key resolutions approved include:
- Approval of a year-end dividend of 98 JPY per share
- Re-election of ten Directors not serving on the Audit and Supervisory Committee, including CEO Christophe Weber and seven External Directors
- Approval of executive bonuses totaling up to 460 million JPY for two eligible Directors (excluding overseas Directors and External Directors)
The meeting also reviewed the Business Report, Consolidated Financial Statements, and Unconsolidated Financial Statements, along with audit results from the Accounting Auditor and Audit and Supervisory Committee. This filing demonstrates Takeda's commitment to corporate governance and shareholder transparency.
FAQ
What is the current stock price of Takeda Pharm (TAK)?
What is the market cap of Takeda Pharm (TAK)?
What is the core focus of Takeda Pharmaceutical?
How does Takeda generate its revenue?
In which therapeutic areas does Takeda specialize?
What is Takeda's global market presence?
How does Takeda enhance its research and development efforts?
What strategies does Takeda use to remain competitive?
How does Takeda differentiate itself from its competitors?
